Beacon Investment Advisory Services Inc. boosted its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 63.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 94,237 shares of the company's stock after buying an additional 36,571 shares during the period. Beacon Investment Advisory Services Inc. owned about 0.11% of HealthEquity worth $8,511,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Acumen Wealth Advisors LLC purchased a new position in shares of HealthEquity in the fourth quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd lifted its position in shares of HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock valued at $28,000 after acquiring an additional 293 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of HealthEquity in the 4th quarter valued at approximately $28,000. Leonteq Securities AG boosted its stake in HealthEquity by 159.9% in the 1st quarter. Leonteq Securities AG now owns 382 shares of the company's stock worth $32,000 after purchasing an additional 235 shares during the period. Finally, Axiom Investment Management LLC acquired a new position in HealthEquity in the 1st quarter worth approximately $33,000. 99.55% of the stock is owned by hedge funds and other institutional investors.
HealthEquity Stock Up 1.2%
HealthEquity stock opened at $104.63 on Friday. The company has a current ratio of 3.44, a quick ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity, Inc. has a 1-year low of $72.76 and a 1-year high of $106.42. The firm's fifty day simple moving average is $93.37 and its 200-day simple moving average is $85.79. The company has a market capitalization of $8.75 billion, a P/E ratio of 39.19, a P/E/G ratio of 1.74 and a beta of 0.21.
HealthEquity (NASDAQ:HQY - Get Free Report) last issued its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.11 by $0.13. The firm had revenue of $354.64 million during the quarter, compared to analysts' expectations of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. HealthEquity's quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts forecast that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several brokerages have issued reports on HQY. Royal Bank Of Canada boosted their target price on shares of HealthEquity from $100.00 to $108.00 and gave the company an "outperform" rating in a research note on Wednesday, June 3rd. KeyCorp reaffirmed an "overweight" rating on shares of HealthEquity in a research report on Tuesday, May 26th. Barrington Research reiterated an "outperform" rating and set a $110.00 price target on shares of HealthEquity in a report on Friday, May 22nd. Citizens Jmp upped their price target on HealthEquity from $110.00 to $111.00 and gave the company a "market outperform" rating in a research report on Monday, June 1st. Finally, Weiss Ratings raised HealthEquity from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, June 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $110.93.
Get Our Latest Research Report on HQY
Insiders Place Their Bets
In related news, Director Gayle Furgurson Wellborn sold 2,439 shares of the business's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the completion of the sale, the director directly owned 19,733 shares in the company, valued at approximately $1,775,970. The trade was a 11.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,354 shares of the company's stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $95.00, for a total value of $223,630.00. Following the sale, the executive vice president directly owned 52,244 shares of the company's stock, valued at $4,963,180. The trade was a 4.31% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,905 shares of company stock valued at $1,651,280 over the last quarter. Insiders own 1.60% of the company's stock.
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc NASDAQ: HQY is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.